1. Scrip
  2. >>New Products

AbbVie Expected To Ditch Abicipar After US FDA Setback

 
• By Joseph Haas

With a complete response letter for wet AMD drug abicipar, AbbVie is expected to move on from the drug acquired with Allergan. Molecular Partners now seems inclined to focus on IO, virology.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
FDA determined that abicipar's benefit don't outweigh its risk of intraocular inflammation

AbbVie Inc. seems unlikely to invest further resources or effort into anti-VEGF drug abicipar pegol for wet age-related macular degeneration (AMD) following a US Food and Drug Administration complete response letter on 26 June, and Molecular Partners AG, which discovered and initially developed the candidate, also appears to be positioning away from ophthalmology to increase its focus on cancer and virology programs.

Both companies announced the CRL on 26 June, noting that the FDA decided the drug has an unfavorable benefit-risk ratio...

More from New Products

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.